Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma

Completed · Phase 1/Phase 2

Conditions studied: Intraocular Melanoma, Melanoma (Skin)

In brief

RATIONALE: Biological therapies, such as MDX-010, work in different ways to stimulate the immune system and stop tumor cells from growing. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Combining monoclonal antibody therapy with interleukin-2 may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combining monoclonal antibody therapy with interleukin-2 in treating patients who have metastatic melanoma.

Key facts

Study ID

NCT00058279

Run by

National Cancer Institute (NCI)

Starts

2003-02-01

Expected to finish

2006-08-01

Last updated by the study team

2013-06-20

Who can join

Age: 16 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support — Bethesda, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.